- Home
- AVBC vs CLLS Comparison
AVBC vs CLLS Comparison
Compare AVBC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVBC | CLLS |
|---|---|---|
| Founded | 1869 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.6M | 394.4M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVBC | CLLS |
|---|---|---|
| Price | $23.77 | $1.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $27.25 | $4.83 |
| AVG Volume (30 Days) | ★ 97.5K | 94.7K |
| Earning Date | 10-22-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.43 | $10.70 |
| P/E Ratio | $33.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.84 | $0.88 |
| 52 Week High | $23.72 | $5.45 |
Technical Indicators
Market Signals| Indicator | AVBC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 76.63 | 36.03 |
| Support Level | $21.59 | $0.88 |
| Resistance Level | N/A | $2.99 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 90.09 | 39.88 |
Price Performance
Historical ComparisonAbout AVBC Avidia Bancorp Inc.
Avidia Bancorp Inc business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial and industrial loans, one-to four-family residential mortgage loans, and commercial real estate loans.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.